Literature DB >> 16762739

Plague: disease, management, and recognition of act of terrorism.

Janak Koirala1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16762739     DOI： 10.1016/j.idc.2006.02.004

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN： 0891-5520            Impact factor:   5.982


× No keyword cloud information.
  7 in total

1.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

2.  A bivalent typhoid live vector vaccine expressing both chromosome- and plasmid-encoded Yersinia pestis antigens fully protects against murine lethal pulmonary plague infection.

Authors:  James E Galen; Jin Yuan Wang; Jose A Carrasco; Scott A Lloyd; Gabriela Mellado-Sanchez; Jovita Diaz-McNair; Olga Franco; Amanda D Buskirk; James P Nataro; Marcela F Pasetti
Journal:  Infect Immun       Date:  2014-10-20       Impact factor: 3.441

3.  A parenteral DNA vaccine protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Richard Bowen; Sarah Golden; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

4.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

Review 5.  Innate immune response during Yersinia infection: critical modulation of cell death mechanisms through phagocyte activation.

Authors:  Tessa Bergsbaken; Brad T Cookson
Journal:  J Leukoc Biol       Date:  2009-09-04       Impact factor: 4.962

6.  Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges.

Authors:  Mary Kate Hart; George A Saviolakis; Susan L Welkos; Robert V House
Journal:  Adv Prev Med       Date:  2011-10-17

Review 7.  Plague: past, present, and future.

Authors:  Nils Chr Stenseth; Bakyt B Atshabar; Mike Begon; Steven R Belmain; Eric Bertherat; Elisabeth Carniel; Kenneth L Gage; Herwig Leirs; Lila Rahalison
Journal:  PLoS Med       Date:  2008-01-15       Impact factor: 11.069
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.